thalidomide has been researched along with Plasmablastic Diffuse Large B-cell Lymphoma in 6 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "No standard of care is established for plasmablastic lymphoma (PBL) and prognosis remains extremely poor, given that patients relapse early after chemotherapy and display resistance to commonly applied cytostatic drugs." | 1.48 | A patient with plasmablastic lymphoma achieving long-term complete remission after thalidomide-dexamethasone induction and double autologous stem cell transplantation: a case report. ( Agostinelli, C; Argnani, L; Broccoli, A; Cavo, M; Nanni, L; Stefoni, V; Zinzani, PL, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Broccoli, A | 1 |
| Nanni, L | 1 |
| Stefoni, V | 1 |
| Agostinelli, C | 1 |
| Argnani, L | 1 |
| Cavo, M | 1 |
| Zinzani, PL | 1 |
| Carras, S | 1 |
| Regny, C | 1 |
| Peoc'h, M | 1 |
| Gervasoni, J | 1 |
| Gressin, R | 1 |
| Cahn, JY | 1 |
| Molina, L | 1 |
| Yanamandra, U | 1 |
| Sahu, KK | 1 |
| Jain, N | 1 |
| Prakash, G | 1 |
| Saikia, U | 1 |
| Malhotra, P | 1 |
| Gui, L | 1 |
| He, XH | 1 |
| Liu, P | 1 |
| Yang, JL | 1 |
| Qin, Y | 1 |
| Zhou, SY | 1 |
| Yang, S | 1 |
| Zhang, CG | 1 |
| Shi, YK | 1 |
| Pretscher, D | 1 |
| Kalisch, A | 1 |
| Wilhelm, M | 1 |
| Birkmann, J | 1 |
| Schmit, JM | 1 |
| DeLaune, J | 1 |
| Norkin, M | 1 |
| Grosbach, A | 1 |
1 review available for thalidomide and Plasmablastic Diffuse Large B-cell Lymphoma
| Article | Year |
|---|---|
Refractory plasmablastic lymphoma-a review of treatment options beyond standard therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Drug Resistance, Neoplasm | 2017 |
5 other studies available for thalidomide and Plasmablastic Diffuse Large B-cell Lymphoma
| Article | Year |
|---|---|
A patient with plasmablastic lymphoma achieving long-term complete remission after thalidomide-dexamethasone induction and double autologous stem cell transplantation: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Hematopoietic Stem Cell Trans | 2018 |
Dramatic efficacy of low dose lenalidomide as single agent in a patient with refractory gastric non-human immunodeficiency virus-associated plasmablastic lymphoma.
Topics: Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Le | 2015 |
Plasmablastic lymphoma: successful management with CHOP and lenalidomide in resource constraint settings.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans | 2016 |
[Clinical features and outcomes: analysis of 9 cases of HIV-negtive plasmablastic lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival | 2016 |
A Case of Plasmablastic Lymphoma Achieving Complete Response and Durable Remission after Lenalidomide-Based Therapy.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Computed Tomography Angiography; | 2017 |